Patents by Inventor David Lewis Earnest

David Lewis Earnest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Organic Compounds
    Publication number: 20090221665
    Abstract: The present invention relates to a combination of a 5-HT4 receptor agonist and a cholinesterase inhibitor and pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination may be employed for the treatment of altered gastrointestinal motility, sensitivity, secretion or abdominal disorders. The dosage is preferably oral. The preferred 5-HT4 receptor agonist is tegaserod.
    Type: Application
    Filed: December 20, 2006
    Publication date: September 3, 2009
    Inventor: David Lewis Earnest
  • Compositions and Methods for Treating Diseases
    Publication number: 20090163551
    Abstract: This invention relates to methods for treating, preventing and/or managing gastric injury, e.g., NSAID-induced gastric injury in a subject including administering to the subject tegaserod, alone or in combination with a proton pump inhibitor. Also provided are compositions and kits for use in methods of the invention.
    Type: Application
    Filed: June 13, 2007
    Publication date: June 25, 2009
    Applicant: Novartis AG
    Inventor: David Lewis Earnest
  • Organic Compounds
    Publication number: 20080161307
    Abstract: A method for the treatment of delayed gastric emptying, in a patient in need of such treatment, which comprises administering an effective amount of a 5-HT4 agonist, e.g. tegaserod or salts or hydrates thereof, to the patient.
    Type: Application
    Filed: January 27, 2006
    Publication date: July 3, 2008
    Inventors: David Lewis Earnest, Mikhail Rojavin, Gervais Tougas
  • Method for the prevention of colonic adenomas
    Patent number: 6677328
    Abstract: Method for the prevention of colonic adenomas in mammals at risk of developing them by administering to such mammals an effective colonic adenoma preventive amount of ursodiol or a pharmaceutically acceptable salt conjugation product thereof.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: January 13, 2004
    Assignees: Novartis Corp., University of Chicago, University of Arizona
    Inventors: Carroll Wayne Allen, Thomas Albert Brasitus, David Lewis Earnest, Gerald Leigh Messerschmidt